19.35

1.12% -0.22

After Hours: 19.74 0.39 +2.02%

Monte Rosa Therapeutics Inc (GLUE)

Overview News Price History Option Chain Financials Why GLUE Down? Discussions Forecast

Monte Rosa Therapeutics Inc stock is traded at $19.35, with a volume of 556.59K. It is down -1.12% in the last 24 hours and up +13.22% over the past month. Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).

Previous Close:

$19.57

Open:

$19.82

24h Volume:

556.59K

Relative Volume:

0.53

Market Cap:

$1.55B

Revenue:

$123.67M

Net Income/Loss:

$-38.63M

P/E Ratio:

-31.36

EPS:

-0.617

Net Cash Flow:

$-27.50M

1W Performance:

+1.79%

1M Performance:

+13.22%

6M Performance:

+57.19%

1Y Performance:

+317.93%

1-Day Range:

$18.82

$19.97

1-Week Range:

$18.50

$19.97

52-Week Range:

$3.51

$25.77

Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile

Name

Monte Rosa Therapeutics Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

617-949-2643

Address

321 HARRISON AVENUE, BOSTON

Employee

150

Twitter

Next Earnings Date

2026-05-14

Latest SEC Filings

GLUE's Discussions on Twitter

Compare GLUE vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GLUE Monte Rosa Therapeutics Inc	19.35	1.57B	123.67M	-38.63M	-27.50M	-0.617
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-19-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Feb-15-24	Initiated	Wedbush	Outperform
Jan-03-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Oct-13-22	Initiated	UBS	Buy
Aug-15-22	Initiated	Jefferies	Buy
Apr-28-22	Initiated	Credit Suisse	Neutral
Feb-10-22	Initiated	Wells Fargo	Equal Weight
Oct-14-21	Initiated	SVB Leerink	Mkt Perform

View All

Monte Rosa Therapeutics Inc Stock (GLUE) Latest News

04:05 AM

Planned Monte Rosa (GLUE) CEO share sale under Rule 10b5-1 - Stock Titan

04:05 AM

04:01 AM

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

04:01 AM

May 03, 2026

Dunn Edmund, principal accounting officer, sells Monte Rosa (GLUE) shares for $2496 - Investing.com

May 03, 2026

May 02, 2026

Form 144 | Monte Rosa Therapeutics(GLUE.US) Officer Proposes to Sell 103.45 Million in Common Stocks - Moomoo

May 02, 2026

May 01, 2026

Monte Rosa Therapeutics (GLUE) Form 144: RSU 21,865; Markus Warmuth sales listed - Stock Titan

May 01, 2026

Apr 30, 2026

GLUE SEC FilingsMonte Rosa Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 30, 2026

Monte Rosa Therapeutics (GLUE) Projected to Post Quarterly Earnings on Thursday - MarketBeat

Apr 30, 2026

Short Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Expands By 18.2% - MarketBeat

Apr 30, 2026

Apr 29, 2026

[ARS] Monte Rosa Therapeutics, Inc. SEC Filing - Stock Titan

Apr 29, 2026

Executive pay and audits headline Monte Rosa (NASDAQ: GLUE) 2026 proxy - Stock Titan

Apr 29, 2026

Apr 24, 2026

GLUE Price Today: Monte Rosa Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange

Apr 24, 2026

Apr 23, 2026